FDA approves first radioligand equivalent, Curium's copycat of Novartis' Lutathera

The FDA approved Curium's Bexlutry, the first generic equivalent radioligand therapy referencing Novartis’ Lutathera for gastroenteropancreatic neuroendocrine tumors, marking a significant move towards radioligand therapy generics in the US.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.